Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicus Pharma Ltd. (MDCXW) files reports with the U.S. Securities and Exchange Commission that provide detailed information on its material agreements, financial obligations, and corporate structure. As a clinical-stage holding company in the pharmaceutical preparations and biotechnology space, these filings are a primary source for understanding how the company finances and supports its life sciences activities.
Among its disclosures, Medicus Pharma Ltd. has reported entering into a securities purchase agreement with an institutional investor involving the issuance of a debenture. The related Form 8-K describes key terms such as the principal amount, interest rate, maturity date, repayment schedule, and optional redemption rights. It also explains how net proceeds were used to satisfy an existing debenture balance and cover discounts and fees, and notes that subsidiaries entered into a global guaranty agreement to back the company’s obligations.
On this SEC filings page, users can access documents such as current reports on Form 8-K, along with other periodic or transactional filings as they become available through EDGAR. These materials can include information on direct financial obligations, material definitive agreements, and exhibits like debentures, purchase agreements, guaranty agreements, and related press releases.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of complex documents, highlight key terms, and help readers interpret items such as debt covenants, repayment structures, and subsidiary guarantees. Real-time updates from EDGAR, along with access to exhibits and other disclosures, allow investors and researchers to review Medicus Pharma Ltd.’s regulatory history and capital structure without manually parsing every filing.
Medicus Pharma Ltd. reported that President and CFO Carolyn F. Bonner received a grant of stock options as equity compensation. She was awarded options for 100,000 Common Shares at an exercise price of $0.50 per share, giving her the right to buy shares at that price in the future.
The options become exercisable on March 26, 2027 and expire on March 27, 2031. Following this grant, Bonner holds stock options covering 100,000 shares. This is an acquisition of derivative securities, not an open‑market purchase or sale of the company’s stock.
Medicus Pharma Ltd. Chief Executive Officer Raza Bokhari received a grant of stock options for 325,000 Common Shares. The options have an exercise price of $0.50 per share and were awarded at no cost on the grant date.
The options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031 if not exercised. Following this grant, Bokhari holds stock options covering a total of 325,000 underlying Common Shares directly as reported in this filing.
Medicus Pharma Ltd. director Ashton William received a grant of stock options, giving him the right to acquire 25,000 common shares. The options have an exercise price of $0.50 per share and expire in 2031. Following this compensation award, he holds options covering 25,000 shares directly.
Medicus Pharma Ltd. is a clinical-stage biotech company developing two main assets: SkinJect’s doxorubicin-containing microneedle array (D‑MNA) for non‑melanoma skin cancers and Antev’s Teverelix, a long‑acting GnRH antagonist for advanced prostate cancer and acute urinary retention.
The company completed a reverse takeover of SkinJect in 2023, listed on Nasdaq in 2024, and voluntarily delisted from the TSX Venture Exchange in 2025. As of March 17, 2026, it had 39,362,109 common shares outstanding and a non‑affiliate market value of about $28.3 million as of June 30, 2025.
SkinJect’s Phase 1 trial met safety and secondary efficacy endpoints, and a 90‑patient Phase 2 study (SKNJCT‑003) in nodular BCC has completed enrollment, with topline data showing the 200 µg dose achieving 73% clinical and 40% histological clearance at Day 57. A UAE Phase 2 trial (SKNJCT‑004) is also underway.
In August 2025, Medicus acquired 98.6% of Antev for roughly $2.97 million in cash plus 1,603,164 shares, with up to $65 million in contingent FDA milestone payments. Teverelix holds composition and process patents out to 2039 and beyond, with FDA‑cleared Phase 2b programs in both advanced prostate cancer and acute urinary retention.
Medicus maintains extensive microneedle IP licensed from the University of Pittsburgh, global Teverelix patents, and several non‑binding collaborations, including with HelixNano on mRNA‑based vaccines and Reliant AI on AI‑driven clinical development. The company has 16 full‑time employees and qualifies as an emerging growth and smaller reporting company, allowing scaled U.S. disclosure requirements.
Medicus Pharma Ltd. reported that it sold a total of 4,471,038 common shares to YA II PN, Ltd. (Yorkville) under a previously disclosed Standby Equity Purchase Agreement. These unregistered sales, completed between December 19, 2025 and March 6, 2026, generated approximate aggregate consideration of $3,846,910.
The company has used part of the net proceeds to prepay a portion of an outstanding debenture held by Yorkville, reducing that obligation. The shares were issued in private transactions relying on the Section 4(a)(2) exemption from registration, and Yorkville may resell them under an effective registration statement while Medicus may request additional share purchases under the SEPA, subject to its conditions and limitations.
Medicus Pharma Ltd. has filed a resale registration covering up to 4,020,000 common shares issuable on exercise of existing Private Warrants held by Armistice Capital Master Fund Ltd. Each warrant is immediately exercisable for one common share at an exercise price of $2.00 and expires on June 5, 2031.
The company is not selling shares in this registration and will not receive proceeds from resales by the selling shareholder, though it may receive up to $8,040,000 if the warrants are exercised for cash. Common shares trade on Nasdaq under “MDCX,” and the company qualifies as an emerging growth and smaller reporting company.
Medicus Pharma Ltd. filed an offering circular supplement dated September 18, 2025 registering 1,490,000 common shares issuable upon the exercise of outstanding warrants.
Concurrently, the company entered into a securities purchase agreement with YA II PN, Ltd. (Yorkville) for a $8,000,000 debenture. Net proceeds were approximately $5.7 million after satisfaction of an existing $1.7 million debt balance and fees. The Debenture bears interest at 8.00% per annum (increasing to 18.00% upon certain defaults), matures on September 17, 2026, and requires monthly repayments of $650,000 plus accrued interest beginning 45 days after issuance. Each subsidiary entered into a global guaranty in favor of Yorkville.
Medicus Pharma Ltd. entered into a new financing deal with YA II PN, Ltd. (Yorkville), issuing a debenture with a principal amount of $8,000,000. The company received approximately $5.7 million in net proceeds after using about $1.7 million to fully repay remaining debentures from a May 2025 financing and accounting for original issue discount and fees. The debenture carries 8.00% annual interest, which can increase to 18.00% if certain events of default occur, and matures on September 17, 2026. Medicus must make monthly payments of $650,000 plus accrued interest in cash starting 45 days after issuance, with any remaining balance due at maturity. All company subsidiaries entered into a global guaranty in favor of Yorkville, and the company may redeem the debenture early in cash, in whole or in part.